e-Therapeutics plc Notice of AGM and Posting of Annual Report (6255L)
17 Mayo 2022 - 1:01AM
UK Regulatory
TIDMETX
RNS Number : 6255L
e-Therapeutics plc
17 May 2022
e-therapeutics plc
("e-therapeutics" or the "Company")
Notice of Annual General Meeting and Posting of Annual Report
and Accounts
London, UK, 17 May 2022 - e-therapeutics plc (AIM: ETX; OTCQX;
ETXPF), a specialist in computational drug discovery with a focus
on developing RNA interference ("RNAi") therapeutics, announces
that its Annual Report and Accounts for the year ended 31 January
2022, which includes the notice of its 2022 Annual General Meeting
("AGM") have been posted to shareholders today and are available on
the Company's website at:
https://www.etherapeutics.co.uk/application/files/1216/5167/3296/ETX_AR_2022.pdf
The AGM will be held at 12:30p.m. on 19 July 2022 at 4 Kingdom
Street, Paddington, London, W2 6BD.
The right to attend and vote at the AGM is determined by
reference to the Company's register of members. Only a member
entered in the register of members as at close of business on 15
July 2022 (or, if the AGM is adjourned, in the register of members
as at the close of business on the date which is two business days
before the time of the adjourned AGM) is entitled to attend and
vote at the AGM.
Shareholders who wish to register their votes on the resolutions
to be put to the AGM should do so by completing and signing the
proxy form that accompanies the notice of the AGM (or appoint a
proxy electronically if their shares are held in CREST) in
accordance with the instructions printed on the proxy form.
Please complete and return the form of proxy in accordance with
the instructions printed thereon as soon as possible and, in any
event, so that it is received by the Company's registrar, Neville
Registrars Limited, Neville House, Steelpark Road, Halesowen, B62
8HD not later than 12:30p.m. on 15 July 2022.
If you do not have a proxy form and believe that you should have
one, or if you have any additional queries on voting, please
contact Neville Registrars Limited.
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
James Chandler, VP IR & Strategic Communications 8888
www.etherapeutics.co.uk
--------------------------
SP Angel Corporate Finance LLP
Tel: +44(0)20 3470 0470
--------------------------
Nominated Adviser and Broker
--------------------------
Matthew Johnson/Caroline Rowe (Corporate
Finance)
--------------------------
Vadim Alexandre/Rob Rees (Corporate Broking)
--------------------------
About e-therapeutics plc
e-therapeutics plc is a UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e- therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV, iTeos and a
US-based, top 5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAFMMTMTMBBTT
(END) Dow Jones Newswires
May 17, 2022 02:01 ET (06:01 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024